CClinicalTrials.gg
CompletedNCT04019405FRAIL_HEARTUpdated Apr 4, 2022

Assessing Frailty in Elderly Patients Who Have Ischemic Heart Disease

An observational study in Frail Elderly, sponsored by Hull University Teaching Hospitals NHS Trust. Completed at 1 site in United Kingdom. Open to participants aged 80 Years and older. Per ClinicalTrials.gov, last updated 2022-04-04.

Sponsored by Hull University Teaching Hospitals NHS Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
80 Years and older
Sex
All
01

Study summary

Participants aged 80 years or over, who attend Castle Hill Hospital with either stable angina or an acute coronary syndrome will be invited to participate in the study. After induction into the study, these participants will be assessed for frailty and quality of life (QoL) using predetermined assessment tools. Quality of life (QoL) will be assessed using the standardised SF-12 questionnaire proforma. Frailty assessment will be based on the use of the Fried Frailty Phenotype criteria and the Edmonton Frailty Scale. Patients will be reassessed at 3,9 and 24 months for their clinical outcomes, repeat frailty assessment and quality of life.

Read the detailed description

STUDY SETTINGS: Cardiology and cardiothoracic out-patients and in-patient wards of Castle Hill hospital

SAMPLE SIZE CALCULATION: FRAIL-HEART is a preliminary observational study designed to evaluate the practicality of undertaking frailty assessments in this population. The sample size of n=150 is estimated on the basis of feasibility. Investigators aim to recruit all consecutive patients who attend our department over a 1 year period. With an expected drop-out rate of 10% , investigators anticipate that it will be feasible to enrol 150 patients in the required time-frame.

PARTICIPANTS: The study target population will be patients aged 80 years or more, who are admitted or referred to the cardiology department because of underlying coronary artery disease.

IDENTIFICATION \& RECRUITMENT: These participants will be recruited into the study from outpatient cardiology clinics and from identification of suitable inpatients admitted to the cardiology and cardiothoracic units.

BASELINE ASSESSMENT: The baseline assessment will include gathering patient baseline demographic data, current diagnosis and clinical status, assessment of the comorbid conditions, and information regarding relevant investigation results including blood results, electrocardiogram (ECG), echocardiogram and coronary angiography data. Participants will be asked to complete QoL questionnaire and undergo the frailty assessments. This will entail completion of several questionnaires.

SF-12 QoL QUESTIONNAIRE: This questionnaire of 12 questions have been extensively used in research practice and validated to assess QoL in a variety of clinical settings20.

FRAILTY ASSESSMENT: This will be evaluated using both the Fried phenotype and Edmonton frailty scale. Study participants will first be asked to complete the written questionnaires. They will then have a measure of handgrip strength and if feasible will be asked to do 'get up and go' and 'five metre walk 'test as detailed in the Edmonton and Fried assessments respectively. Participants who are unable to walk will be marked as per the criteria. Where applicable, participants will be allowed to use walking aids as required.

Where applicable, the research team will also evaluate the results of coronary angiography and will undertake both SYNTAX as well as EUROSCORE calculations.

FOLLOW UP ASSESSMENTS: The study participants will be seen at 3, 9 and 24 month intervals and will be asked to complete the QoL questionnaire and undergo frailty assessment. The following variables will be recorded at each follow-up visit.

  • Patient symptoms- CCS angina class, NYHA class
  • Height, weight, BMI, Vital signs
  • Medication with dosages
  • Document all major adverse outcomes: myocardial infarction, acute cerebrovascular event, major bleeding, or unplanned re-hospitalisation.
  • Document any other adverse events such as kidney injury, transient ischaemic attack.
  • Document length of stay on ICU and total length of hospital stay (where applicable).
  • SF-12 questionnaire
  • Fried Frailty phenotype
  • Edmonton frailty scale
  • Patient perspective survey form- Two separate patients perspective have been developed depending whether the study participants are managed medically or undergo intervention and cardiac surgery.

DEATHS DURING THE STUDY PERIOD: Due to the advanced age of the study participants, it is expected that some patients might die during the study period. In such a situation the data already gathered will be retained in the study. Investigators will be advised to check on the Hull and East Yorkshire NHS Trust record systems before sending out any follow up appointments. The participant's family and relatives will not be approached after their death.

02

Conditions studied

  • Frail Elderly

Keywords

  • coronary artery disease
  • elderly
  • revascularisation
  • frailty
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's enrollment of 150 is below the median of 294 across 1,241 observational studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Hull University Teaching Hospitals NHS Trust is the lead sponsor of 93 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
80 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients (male and female) aged 80 and over and who have a primary diagnosis of ischaemic heart disease will be eligible for participation in the study.

Inclusion criteria

Aged 80 years and above and either

  1. Have been seen in the cardiology out-patient department with a diagnosis of stable angina
  2. Have been admitted to Castle Hill Hospital with non-ST elevation acute myocardial infarction (NSTEMI)
  3. Have been admitted to Castle Hill Hospital with ST-elevation acute myocardial infarction (STEMI)
  4. Have been referred to Castle Hill Hospital for coronary angioplasty
  5. Have been referred to Castle Hill Hospital for coronary artery bypass graft surgery

Exclusion criteria

Exclusion Criteria:

Patients will be excluded from the study in the event of any of the following:

  1. Patients who are unable to provide informed consent including those with advanced dementia.
  2. Patients, who are not able to speak good English sufficiently to be able to understand the study information, give consent and complete study measures.
  3. Patients who have a primary diagnosis of significant valvular disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (actual)
Patient registry
No

Groups and cohorts

  • Frailty status

    Frailty status will be determined by prespecified assessment tools in the study protocol. These assessment tools will be Fried Frailty phenotype model and edmonton frailty Scale.

06

What researchers measure

Primary outcomes

  1. Change in Quality Of Life Questionnaire

    The primary out come will be quality of life assessed by SF-12 survey forms

    Time frame: baseline and 3, 9 and 24 months

Secondary outcomes

  1. Change in frailty Status - Fried frailty Criteria

    To evaluate changes in frailty using the Fried frailty criteria.

    Time frame: baseline and 3, 9 and 24 months

  2. Change in frailty Status - Edmonton Frailty Score

    To evaluate changes in frailty using the Edmonton frailty score.

    Time frame: baseline and 3, 9 and 24 months

  3. Major adverse clinical events during hospitalization

    To evaluate major adverse clinical event (MACE) (defined as a composite of death, acute myocardial infarction, acute cerebrovascular event (CVA), and major bleeding) occurring during hospitalisation for frail versus non-frail participants of study.

    Time frame: baseline and 3, 9 and 24 months

  4. Major Adverse Clinical Event

    To evaluate major adverse clinical event (MACE) (defined as a composite of death, acute myocardial infarction, acute cerebrovascular event (CVA), major bleeding, and unplanned rehospitalisation occurring at 24 months follow-up for frail versus non-frail participants of the study.

    Time frame: 24 months

  5. Predictors of adverse outcome

    Patients' variables will be evaluated to determine the independent predictors of an adverse outcome (defined as death or a worsening in QOL at follow-up).

    Time frame: baseline and 3, 9 and 24 months

07

Study locations

1 site
  • Castle Hill Hospital
    Cottingham, East Riding Of Yorkshire NHS Trust HU16 5JQ, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — individual participant data will not be shared

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04019405
Lead sponsor
Hull University Teaching Hospitals NHS Trust
Responsible party
Sponsor
First posted
Jul 15, 2019
Start date
Jul 2016
Primary completion
Jun 2020
Completion
Dec 2020
Last update
Apr 4, 2022

Study contacts

Angela Hoye, MB.ChB,PhD
principal investigator · Hull and East Yorkshire NHS Trust

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion